Compare ARDX & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | INMD |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 975.9M | 857.4M |
| IPO Year | 2014 | 2018 |
| Metric | ARDX | INMD |
|---|---|---|
| Price | $3.42 | $14.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | $15.14 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 3.9M | 449.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $37.75 | $1.74 |
| Revenue Next Year | $34.24 | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $12.72 |
| 52 Week High | $8.40 | $16.74 |
| Indicator | ARDX | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 24.11 | 29.79 |
| Support Level | N/A | $14.19 |
| Resistance Level | $3.92 | $14.60 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 14.53 | 6.59 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.